Research programme: neurokinin receptor antagonists - sanofi-aventis

Drug Profile

Research programme: neurokinin receptor antagonists - sanofi-aventis

Latest Information Update: 29 Apr 2008

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Small molecules
  • Mechanism of Action Neurokinin 2 antagonists; Neurokinin 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Irritable bowel syndrome; Major depressive disorder

Most Recent Events

  • 08 Mar 2007 Preclinical development is ongoing for depression, irritable bowel syndrome, schizophrenia and anxiety
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 08 Jul 2003 Preclinical trials in Chronic obstructive pulmonary disease in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top